SCHEMBL17607366

SCHEMBL17607366

CC(=O)CN(C)c1ncc(C(=O)O)s1

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
TMPRSS15 P98073 9/20 0.41
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
AGTR1 P30556 3/20 0.34
AGTR2 P50052 3/20 0.34
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HCAR3 P49019 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24853458 0.79 HCAR2 (0.57) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL25410152 0.75 TMPRSS15 (0.59) HCAR2TMPRSS15
SCHEMBL2435872 0.75 ALDH1A1 (0.46) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL17607365 0.74 HCAR2 (0.47) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL15530378 0.74 KDM4E (0.48) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL25408977 0.74 TMPRSS15 (0.60) HCAR2TMPRSS15ALDH1A1
SCHEMBL25410683 0.73 TMPRSS15 (0.61) HCAR2TMPRSS15ALDH1A1
SCHEMBL31482107 0.73 MLYCD (0.44) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL6496980 0.68 HCAR2 (0.44) HCAR2TMPRSS15KDM4EALDH1A1AGTR1
SCHEMBL8198536 0.68 TMPRSS15 (0.42) TMPRSS15KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3194367-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES Boehringer Ingelheim International GmbH (DE) 2017-07-26 EP disclosed
WO-2016041845-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-03-24 WO disclosed